Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / The effects of BMS-470539 on lipopolysaccharide-induced acute lung injury.

< BACK TO ARCHIVE


2019 May


Acute Crit Care


http://www.ncbi.nlm.nih.gov/pubmed/31723918?dopt=Abstract


34


2

The effects of BMS-470539 on lipopolysaccharide-induced acute lung injury.

Authors

The effects of BMS-470539 on lipopolysaccharide-induced acute lung injury.
Jang E-A, Kim J-Y, Tin T D, Song J-A, Lee S-H, Kwak S-H
Acute Crit Care. 2019 May; 34(2):133-140.
PMID: 31723918.

Abstract

Overactivation of inflammatory cells, including macrophages and neutrophils, is associated with acute lung injury. BMS-470539 is a selective agonist of melanocortin 1 receptor, which triggers the inhibition of proinflammatory responses, suppressing neutrophil infiltration and protecting tissue. This study evaluated the effects of BMS-470539 on lipopolysaccharide-induced acute lung injury in a mouse model.
Read This Paper